Retinoblastoma: Value of Dynamic Contrast-Enhanced MR Imaging and Correlation with Tumor Angiogenesis

References

1. 1.↵
   1. Abramson DH,
   2. Dunkel IJ,
   3. Brodie SE,
   4. et al

   . Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 2010; 117: 1623– 29

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Gobin YP,
   2. Dunkel IJ,
   3. Marr BP,
   4. et al

   . Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011; 129: 732– 37

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Suzuki S,
   2. Yamane T,
   3. Mohri M,
   4. et al

   . Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 2011; 118: 2081– 87

   CrossRefPubMed
4. 4.↵
   1. Marback EF,
   2. Arias VE,
   3. Paranhos A Jr.,
   4. et al

   . Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 2003; 87: 1224– 28

   Abstract/FREE Full Text
5. 5.↵
   1. Uusitalo MS,
   2. Van Quill KR,
   3. Scott IU,
   4. et al

   . Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001; 119: 41– 48

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Schueler AO,
   2. Hosten N,
   3. Bechrakis NE,
   4. et al

   . High resolution magnetic resonance imaging of retinoblastoma. Br J Ophthalmol 2003; 87: 330– 35

   Abstract/FREE Full Text
7. 7.↵
   1. Lemke AJ,
   2. Kazi I,
   3. Mergner U,
   4. et al

   . Retinoblastoma: MR appearance using a surface coil in comparison with histopathological results. Eur Radiol 2007; 17: 49– 60

   CrossRefPubMed
8. 8.↵
   1. Honavar SG,
   2. Singh AD,
   3. Shields CL,
   4. et al

   . Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002; 120: 923– 31

   PubMedWeb of Science
9. 9.↵
   1. de Graaf P,
   2. van der Valk P,
   3. Moll AC,
   4. et al

   . Contrast-enhancement of the anterior eye segment in patients with retinoblastoma: correlation between clinical, MR imaging, and histopathologic findings. AJNR Am J Neuroradiol 2010; 31: 237– 45

   Abstract/FREE Full Text
10. 10.↵
    1. de Graaf P,
    2. Goricke S,
    3. Rodjan F,
    4. et al

    . Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol 2011; 42: 2– 14

    PubMed
11. 11.↵
    1. Chantada GL,
    2. Dunkel IJ,
    3. Antoneli CB,
    4. et al

    . Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer 2007; 49: 256– 60

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Chantada GL,
    2. Casco F,
    3. Fandino AC,
    4. et al

    . Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 2007; 114: 2083– 89

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Brisse HJ,
    2. Guesmi M,
    3. Aerts I,
    4. et al

    . Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison. Pediatr Radiol 2007; 37: 649– 56

    CrossRefPubMed
14. 14.↵
    1. Rossler J,
    2. Dietrich T,
    3. Pavlakovic H,
    4. et al

    . Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 2004; 164: 391– 94

    PubMedWeb of Science
15. 15.↵
    1. Tofts PS,
    2. Brix G,
    3. Buckley DL,
    4. et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223– 32

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Guo JY,
    2. Reddick WE

    . DCE-MRI pixel-by-pixel quantitative curve pattern analysis and its application to osteosarcoma. J Magn Reson Imaging 2009; 30: 177– 84

    CrossRefPubMed
17. 17.↵
    1. Cho JH,
    2. Cho G,
    3. Song Y,
    4. et al

    . Feasibility of FAIR imaging for evaluating tumor perfusion. J Magn Reson Imaging 2010; 32: 738– 44

    CrossRefPubMed
18. 18.↵
    1. Padhani AR,
    2. Husband JE

    . Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001; 56: 607– 20

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Cho H,
    2. Ackerstaff E,
    3. Carlin S,
    4. et al

    . Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009; 11: 247– 59, 2p

    PubMed
20. 20.↵
    1. Dadiani M,
    2. Margalit R,
    3. Sela N,
    4. et al

    . High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. Cancer Res 2004; 64: 3155– 61

    Abstract/FREE Full Text
21. 21.↵
    1. Egeland TA,
    2. Gaustad JV,
    3. Galappathi K,
    4. et al

    . Magnetic resonance imaging of tumor necrosis. Acta Oncol 2011; 50: 427– 34

    CrossRefPubMed
22. 22.↵
    1. Miles KA

    . Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999; 30: 198– 205

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Saeed M,
    2. Lund G,
    3. Wendland MF,
    4. et al

    . Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation 2001; 103: 871– 76

    Abstract/FREE Full Text
24. 24.↵
    1. Beasley NJ,
    2. Wykoff CC,
    3. Watson PH,
    4. et al

    . Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 5262– 67

    Abstract/FREE Full Text
25. 25.↵
    1. Vaupel P,
    2. Harrison L

    . Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9 (suppl 5): 4– 9

    Abstract/FREE Full Text
26. 26.↵
    1. Jockovich ME,
    2. Suarez F,
    3. Alegret A,
    4. et al

    . Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. Invest Ophthalmol Vis Sci 2007; 48: 5371– 76

    Abstract/FREE Full Text
27. 27.↵
    1. Mineo TC,
    2. Mineo D,
    3. Onorati I,
    4. et al

    . New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis. Ann Surg Oncol 2010; 17: 3022– 29

    CrossRefPubMed
28. 28.↵
    1. Jockovich ME,
    2. Bajenaru ML,
    3. Pina Y,
    4. et al

    . Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Invest Ophthalmol Vis Sci 2007; 48: 2476– 82

    Abstract/FREE Full Text
29. 29.↵
    1. Knopp MV,
    2. Weiss E,
    3. Sinn HP,
    4. et al

    . Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10: 260– 66

    CrossRefPubMedWeb of Science
30. 30.↵
    1. George ML,
    2. Dzik-Jurasz AS,
    3. Padhani AR,
    4. et al

    . Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001; 88: 1628– 36

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Lee SY,
    2. Kim DK,
    3. Cho JH,
    4. et al

    . Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol 2008; 126: 953– 58

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Mattern J,
    2. Koomagi R,
    3. Volm M

    . Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931– 34

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Stitt AW,
    2. Simpson DA,
    3. Boocock C,
    4. et al

    . Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998; 186: 306– 12

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Viglietto G,
    2. Romano A,
    3. Maglione D,
    4. et al

    . Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996; 13: 577– 87

    PubMedWeb of Science
35. 35.↵
    1. Buadu LD,
    2. Murakami J,
    3. Murayama S,
    4. et al

    . Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996; 200: 639– 49

    PubMedWeb of Science
36. 36.↵
    1. Pennasilico GM,
    2. Arcuri PP,
    3. Laschena F,
    4. et al

    . Magnetic resonance imaging in the diagnosis of melanoma: in vivo preliminary studies with dynamic contrast-enhanced subtraction. Melanoma Res 2002; 12: 365– 71

    CrossRefPubMed